

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 4

Confirmation Number	9232
Application Number	10/805,722
Filing Date	March 22, 2004
First Named Inventor	FALOTICO
Group Art Unit	1615
Examiner Name	C. A. Azpuru
Attorney Docket Number	CRD5070USNP

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov). 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application to the USPTO. Time will vary depending upon the individual case.

Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE  STATEMENT BY APPLICANT</b> (use as many sheets as necessary) Sheet 2 of 4	<b>Confirmation Number</b>	9232
	<b>Application Number</b>	10/805,722
	<b>Filing Date</b>	March 22, 2004
	<b>First Named Inventor</b>	FALOTICO
	<b>Group Art Unit</b>	1615
	<b>Examiner Name</b>	C. A. Azpuru
	<b>Attorney Docket Number</b>	CRD5070USNP

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		<b>BREHM</b> , B., et al. "β-Blockers of the Third Generation Inhibit Endothelin-1 Liberation, mRNA Production and Proliferation of Human Coronary Smooth Muscle and Endothelial Cells", Journal of Cardiovascular Pharmacology, 36 (Suppl.1):S501-S403 (2000)	
		<b>CAMPBELL</b> and Campbell, "Cell Biology of Smooth Muscle In Culture: Implications for Atherogenesis", Inter. Angio, 6 p. 73 (1987)	
		<b>CAMPBELL</b> and Campbell, "Phenotypic Modulation of Smooth Muscle Cells in Primary Culture", Chapter 4, Volume 1, p. 39 (1985)	
		<b>CLOWES</b> and Schwartz, "Significance of Quiescent Smooth Muscle Migration in the Injured Rat Carotid Artery", Circulation Research 56, p. 139-145 (1985)	
		<b>EDELMAN</b> , E., et al. "Pathobiologic Responses to Stenting", (ABSTRACT), American Journal of Cardiology, Volume 81, Issue 7, Supplement 1, April 9, 1998 p. 4E-6E	
		<b>FISCHMAN</b> , D., et al. "A Randomized Comparison of Coronary-Stent Placement and Balloon Angioplasty in the Treatment of Coronary Artery Disease", New England Journal of Medicine, Volume 331 No. 9, p. 496-501 (August 1994)	
		<b>FRANKLIN</b> and FAXON, "Pharmacologic Prevention of Restenosis After coronary Angioplasty: Review of the Randomized Clinical Trials", Coronary Artery Disease Vol. 4, No. 3 p. 232 (March 1993)	
		<b>LANG</b> , J., et al. "Effects of Okadaic Acid and ATPyS on Cell Length and Ca <sup>2+</sup> - Channel Currents Recorded in Single Smooth Muscle Cells of the Guinea-Pig Taenia Caeci", Br. J. Pharmacol. 104, p. 331-336 (1991)	
		<b>MAK</b> and TOPOL, "Clinical Trials to Prevent Restenosis After Percutaneous Coronary Revascularization", Annals New York Academy of Sciences, p. 255-288 (1997)	
		<b>POMPA</b> , et al. "Clinical Trials of Restenosis After Coronary Angioplasty", Journal of the American Heart Association (Circulation) 84 p. 1426-1436 (1991)	
		<b>SERRUYS</b> , P., et al. "Heparin-Coated Palmaz-Scharz Stents in Human Coronary Arteries; Early Outcome of the Benestent-II Pilot Study", Circulation, Clinical Investigations and Reports, American Heart Association, Volume 93(3) p. 412-422 1996	
		<b>SERRUYS</b> , P., et al. "A Comparison of Balloon-Expandable-Stent Implantation with Balloon Angioplasty in Patients with Coronary Artery Disease", New England Journal of Medicine, Volume 331 p. 489-495 Number 8, (August 1994)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov). <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary) Sheet 3 of 4	<b>Confirmation Number</b>	9232
	<b>Application Number</b>	10/805,722
	<b>Filing Date</b>	March 22, 2004
	<b>First Named Inventor</b>	FALOTICO
	<b>Group Art Unit</b>	1615
	<b>Examiner Name</b>	C. A. Azpuru
	<b>Attorney Docket Number</b>	CRD5070USNP

		<b>SERRUYS, P., et al.</b> "Evaluation of Ketanserlin in the Prevention of Restenosis After Percutaneous Transluminal Coronary Angioplasty A Multicenter Randomized double-OBlinD Placebo-Controlled Trial", Journal of the American Heart Association, Circulation, 88 p. 1588-1601 (1993)	
		<b>TANAKA, H., et al.</b> "Sustained Activation of Vascular a Cells and Leukocytes in the Rabbit Aorta After Balloon Injury", Circulation, American Heart Association, Vol. 88, p. 1788-1803 (1993)	
		<b>TARDIF, J., et al.</b> "Probucol and Multivitamins in the Prevention of restenosis After coronary Angioplasty", New England Journal of Medicine, Volume 337 p. 365-372 Number 6 (August 1997)	
		<b>TERISTEIN, P., et al.</b> "New England Journal of Medicine", Volume 336 p. 1679-1703 Number 24 (June 1997)	
		<b>YOKOI, H., et al.,</b> "Effectiveness of an Antioxidant in Preventing Restenosis After Percutaneous Transluminal Coronary Angioplasty: The Probucol Angioplasty Restenosis Trial", JACC, Vol. 30, No. 4, p. 855-862 (1997)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.  
 This collection of information is required by 37 CFR 1.97 and 1.98. The information required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application to the USPTO. Time will vary depending upon the individual case.  
 Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.